Programmed cell death 1/programmed cell death ligand‐1 (PD‐1/PD‐L1) inhibitor combined with chemotherapy has emerged as the primary first‐line treatment for driver gene‐negative NSCLC patients with distant metastasis.5, 6. Here, PDCD1 is linked to non-small cell lung carcinoma.